<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02951975</url>
  </required_header>
  <id_info>
    <org_study_id>GMA-EAME-EYE-0368</org_study_id>
    <nct_id>NCT02951975</nct_id>
  </id_info>
  <brief_title>Ozurdex® in Patients With Non-infectious Uveitis Affecting the Posterior Segment of the Eye</brief_title>
  <acronym>Louvre 2</acronym>
  <official_title>Multicentre Longitudinal Study of the Prescription of Ozurdex® in Patients With Non-infectious Uveitis Affecting the Posterior Segment of the Eye</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational study will evaluate the safety, efficacy, characteristics of patients,
      characteristics of physicians and quality of life in patients who are prescribed OZURDEX® as
      treatment for non-infectious uveitis of the posterior segment of the eye in France.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Best Corrected Visual Acuity (BCVA) ≥15 Letters</measure>
    <time_frame>2 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with a Gain (Improvement) in BCVA of at Least 15 Letters from Baseline</measure>
    <time_frame>Baseline, Months 6 and 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in BCVA</measure>
    <time_frame>Baseline, Months 2, 6 and 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Vitreous Haze Score Using a 5-Point Scale</measure>
    <time_frame>Baseline and Months 2, 6 and 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Macular Thickness</measure>
    <time_frame>Baseline, Months 2, 6 and 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Categorized by Comorbidities (Diseases Associated with Inflammation, Other Ophthalmic Diseases, General Comorbidities)</measure>
    <time_frame>18 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ25) Score Using a 25 Item Questionnaire</measure>
    <time_frame>Baseline, Months 2 and 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Repeat Treatments with OZURDEX® and Other Drugs</measure>
    <time_frame>18 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Between Repeat Treatments with OZURDEX® and Other Drugs</measure>
    <time_frame>18 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs)</measure>
    <time_frame>18 Months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Non-infectious Uveitis</condition>
  <arm_group>
    <arm_group_label>OZURDEX®</arm_group_label>
    <description>Patients prescribed dexamethasone intravitreal implant (OZURDEX®) in clinical practice for the treatment of non-infectious uveitis affecting the posterior segment of the eye.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone intravitreal implant</intervention_name>
    <description>Dexamethasone intravitreal implant (OZURDEX®) as prescribed in clinical practice.</description>
    <arm_group_label>OZURDEX®</arm_group_label>
    <other_name>OZURDEX®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with OZURDEX® in clinical practice.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Patient with non-infectious uveitis affecting the posterior segment of the eye.

        Exclusion Criteria:

        -Patient not residing in metropolitan France.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Zanzouri</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Registry Team</last_name>
    <phone>1-800-347-4500</phone>
    <email>IR-CTRegistration@allergan.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique Monticelli</name>
      <address>
        <city>Marseille</city>
        <zip>13 008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Service d'ophtalmologie Centre hospitalier Pasteur 2</name>
      <address>
        <city>Nice</city>
        <zip>06 000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.allerganclinicaltrials.com</url>
    <description>More Information</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2016</study_first_submitted>
  <study_first_submitted_qc>October 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2016</study_first_posted>
  <last_update_submitted>July 24, 2017</last_update_submitted>
  <last_update_submitted_qc>July 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

